Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
taragarestrant + palbociclib
- Development stage
- Unknown
- Lead developer
- InventisBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination of taragarestrant (D-0502), an orally bioavailable selective estrogen receptor degrader (SERD), and palbociclib, a selective CDK4/6 inhibitor. This combination is being investigated for the treatment of estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The combination has shown promising antitumor activity with tolerable toxicity in clinical trials.
02
Targets
ER (Estrogen receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on taragarestrant + palbociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on taragarestrant + palbociclib.